- Open Access
The immune modifying effects of amino acids on gut-associated lymphoid tissue
Journal of Animal Science and Biotechnology volume 4, Article number: 27 (2013)
The intestine and the gut-associated lymphoid tissue (GALT) are essential components of whole body immune defense, protecting the body from foreign antigens and pathogens, while allowing tolerance to commensal bacteria and dietary antigens. The requirement for protein to support the immune system is well established. Less is known regarding the immune modifying properties of individual amino acids, particularly on the GALT. Both oral and parenteral feeding studies have established convincing evidence that not only the total protein intake, but the availability of specific dietary amino acids (in particular glutamine, glutamate, and arginine, and perhaps methionine, cysteine and threonine) are essential to optimizing the immune functions of the intestine and the proximal resident immune cells. These amino acids each have unique properties that include, maintaining the integrity, growth and function of the intestine, as well as normalizing inflammatory cytokine secretion and improving T-lymphocyte numbers, specific T cell functions, and the secretion of IgA by lamina propria cells. Our understanding of this area has come from studies that have supplemented single amino acids to a mixed protein diet and measuring the effect on specific immune parameters. Future studies should be designed using amino acid mixtures that target a number of specific functions of GALT in order to optimize immune function in domestic animals and humans during critical periods of development and various disease states.
It is well established that protein deficiency suppresses the immune response and increases susceptibility to infection. In fact, protein energy malnutrition is hypothesized to be the leading contributor to immune deficiency globally. Although the requirement for protein to support immunity is well defined and part of current recommendations, only recently have investigators begun to explore the potential use of individual dietary amino acids to optimize immune function. Early evidence suggested that amino acids are important energy substrates for immune cells[2–5] and for antioxidant defense mechanisms. There are also critical health states (i.e. burns, trauma, infection, total parenteral (TPN) feeding) or periods of development (i.e. weaning, pregnancy) where it is now accepted that some dietary non-essential amino acids become conditionally essential. These include arginine, glutamine, glutamate, glycine, proline, taurine and cysteine. This change in need for these amino acids in the diet may be due in part because of their effects on immune function.
The intestine serves not only as the main site of nutrient absorption and amino acid metabolism, but is also the largest immune organ in the body. The intestinal epithelium, while facilitating nutrient absorption, also has a major role in protecting the host from oral pathogens, inducing oral tolerance and maintaining a healthy interaction with commensal bacteria. Indeed both protein and single amino acid deficiencies have been shown to impair the physical integrity and growth of the intestinal epithelium, as well as alter the immune response. This manuscript will review our current understanding of Gut- Associated Lymphoid Tissue (GALT) and examine the immunomodulatory effects of specific amino acids on immunity that occurs or originates in the intestine.
The intestinal barrier and the gut associated immune system
GALT, the largest immune organ in the body of humans and domestic animals, contains a variety of immune cell types from the innate and acquired immune systems (as reviewed by). Because of the proximity to the microbiome and the immediate contact with food, it is continually exposed to both ‘normal’ and potentially dangerous antigens. Accordingly, GALT develops in a manner that allows non-pathogenic substances, such as commensal bacteria, to survive and enables tolerance to food antigens, while protecting the host from pathogenic organisms and other potentially toxic substances. GALT is considered a component of the mucosal immune system and is composed of aggregated tissue including Peyer’s patches (PPs) and solitary lymphoid follicles, and non-aggregated cells in the lamina propria, intestinal epithelial cells (IECs), intraepithelial lymphocytes (IELs), as well as mesenteric lymph nodes (MLNs). Collectively, GALT plays a critical role in the development of the systemic immune response. As a primary site of antigen exposure it primes naïve T- and B-lymphocytes that develop into effector cells which migrate from the intestine to other sites of the body to protect against immune challenges, such as invading pathogens (Figure 1).
GALT has an important role in first line mucosal defenses. The epithelium is protected from large pathogens or particles by a layer of mucin, a glycoprotein secreted from the specialized goblet cell within the endothelium. The IELs are dispersed among the IECs that line intestinal villi and both cell types play a role in gut immune function (Figure 1). Tight junction proteins, such as claudin, occludin and ZO-1, determine the mucosal permeability and regulate the flow of solutes between the IECs. IECs are involved in the intestinal immune response and some consider them an integral part of GALT. They can activate or suppress IELs via secretion of anti-microbial peptides, cytokines and chemokines or through the processing and presentation of antigen in the context of MHC Class I and MHC class II molecules to the IELS. IELs are primarily T-cells but have functions distinct from peripheral T-cells. The types of T-cells present vary widely by species and disease states, but the majority are CD8+, CD45RO + (antigen mature), and express adhesion molecules that are thought to be homing signals. In mice and cows/calves, but not humans, the majority of T-cells are γδ T-cell Receptor + (TCR+) and the remainder are αβTCR + [13–15]. The primary role of γδTCR + cells is to induce tolerance and the primary role of the αβTCR + cells is to induce IgA production. The difference between species may be related to the degree of exposure to the microbiota and different dietary exposure and requirements.
The PPs are lymphoid aggregates that line the intestine and colon and are the primary inductive sites of the mucosal humoral immune response (Figure 1). The follicle associated epithelium (FAE) layer of the PP contains highly specialized cells called microfold or M cells that continually sample the intestinal contents bringing them in contact with the resident immune cells (primarily B-cells and small numbers of macrophages, dendritic cells and T-cells). Dendritic cells can also extend through the intestinal epithelial cells to directly sample antigen. Antigen presenting cells, particularly dendritic cells, migrate from the PP or epithelium to the MLN where they educate naïve T-cells. The MLNs act as the interphase between the peripheral immune system and the gut and it is believed that they are the primary sites of oral tolerance induction. Oral tolerance is mechanistically defined as the process by which dendritic cells present peptides to CD4+ T-cells and through a series of signals (cell surface and secreted) induce regulatory T-cells and subsequently the tolerance to the antigen/peptide. In rats, MLN are composed primarily of T-helper cells (55%), but also contain cytotoxic T-cells (15%), B-cells (25%) and dendritic cells (5%). Pigs have slightly different phenotypes, with approximately 12% CD4+ CD8+, 25-28% CD4+ (single positive), 27-32% CD8+ (single positive) and the rest composed of B-cells and other antigen presenting cells.
After exposure to antigen in the PPs and MLNs, immune cells circulate in the periphery and migrate to other mucosal effector sites and home back to the lamina propria (Figure 1). This is the major effector component of GALT as these cells are antigen mature and primed to respond to foreign antigens. The lamina propria is comprised primarily of IgA secreting plasma cells and effector T-cells (50% T-helper and 30% cytotoxic T-cells). Secretory IgA (sIgA) is the most abundant immunoglobulin in the mammalian intestine and acts by binding pathogens and facilitating the entrapment in mucous and removal from the intestinal track. Indeed a deficiency or inability to produce IgA results in frequent intestinal infections.
Amino acids and the immune system
Although it has long been established that adequate nutrition is essential to the development and maintenance of the immune system, there is a rapidly growing body of literature that demonstrates the immune benefits of supplementation with specific nutrients, particularly during critical stages of development or disease states, when animals may have a higher demand for essential and non-essential nutrients. Such states include weaning, infectious diseases or chronic inflammatory conditions. The importance of individual amino acids to gut function and immunity has become apparent in recent years due to studies that have supplemented amino acids to animals/humans fed: 1) intravenously (total parenteral nutrition(TPN)), which demonstrates not only the importance of GALT but also the importance to immune functions beyond the intestine; 2) during weaning, which demonstrates the importance of these amino acids to the normal growth and development of the intestine and GALT; and 3) during infection or chronic inflammation, which has demonstrated the role in regulating inflammation and infectious challenges.
Glutamine has been the most extensively studied amino acid with regards to its effects on GALT and the intestine. In health, glutamine is categorized as a non-essential amino acid and represents the amino acid in highest proportions in the body. However, during periods of stress and during critical stages of development the essentiality of exogenous sources of glutamine is now well-established to support growth and health in young animals.
Role as a precursor and energy substrate for immune and epithelial cells
Glutamine is an important energy substrate and precursor for other amino acids and derivatives in immune cells and enterocytes (Table 1)[2–4, 28]. In fact, both cell types cannot function without at least some exogenous glutamine. In immune cells, particularly lymphocytes, neutrophils and macrophages, glutamine is used rapidly and metabolized to glutamate, aspartate, lactate and CO2. Wu et al. demonstrated the main metabolic fates of glutamine in enterocytes from weaning piglets are ammonia, glutamate, alanine, aspartate and CO2. As a precursor for glutamate, glutamine facilitates the production of glutathione (GSH), an important regulator of redox in enterocytes and lymphocytes. It also provides nitrogen for the synthesis of nucleic acids and proteins that are needed for lymphocytes to proliferate and produce signals such as cytokines.
Effects on intestinal function
In addition to its role as an energy substrate, glutamine is important for intestinal development and function, including maintaining the integrity of the gut barrier, the structure of the intestinal mucosa and redox homeostasis (Table 1).
Experimental evidence suggests that glutamine supplementation to weaning animals is beneficial to intestinal health. Wu et al. first demonstrated that oral supplementation with 1% w/w glutamine prevented the decrease in jejunal villus height that occurs following weaning. Oral supplementation of glutamine (0.5-1.0% w/w) to healthy weaning piglets improves measures of intestinal health, including increasing villus height and crypt depth, reducing oxidative stress, lowering the proportion of apoptotic IECs and increasing the proliferative rates of IECs[33, 34]. Glutamine supplementation has been demonstrated to reduce the adverse effects of TPN on intestinal function in healthy animals. A TPN solution containing 2% w/v glutamine has improved villus length, crypt depth, tight junction protein expression (occludin, JAM1 and ZO-1), and epithelial permeability[35–37].
In addition to the beneficial effects in healthy animals, we and others have demonstrated that glutamine supplementation may be protective to intestinal health during E. coli infection in animals at weaning (Table 1). We previously demonstrated that supplementing the weaning diet of piglets with glutamine (at 4.4% w/w) improved intestinal barrier function (decreased ion movement across mucosa), and maintained tight junction (claudin-1 and occludin) protein expression after an E. coli challenge. Similarly, Yi et al. reported that weaned piglets fed 2% w/w glutamine for 12 days prior to oral E. coli challenge maintained villus height, area and volume similar to uninfected piglets. Suckling piglets supplemented with oral glutamine (3.42 mmol/kg body weight) were protected against LPS-induced damage to the intestine. Glutamine supplementation (5% w/w) was also reported to improve gut barrier function in a rat model of colitis.
Effects on GALT
In vitro and in vivo studies have demonstrated the importance of glutamine to B- and T-lymphocyte, neutrophil and macrophage functions (as reviewed by). In vitro, glutamine supports the proliferative response of T-cells, plasma cell generation, macrophage inflammatory cytokine production and phagocytosis of neutrophils and macrophages. We and others have shown that glutamine supplementation lowers inflammatory cytokine levels, improves intestinal cytokine mRNA expression, increases immunoregulatory cytokine concentrations and increases the proliferative responses of MLN cells to a B- and T-cell mitogen (pokeweed mitogen) in healthy weaning piglets[22, 34, 38, 43]. We also reported a lower proportion of IgA + cells in the MLN of weaning piglets fed glutamine relative to the control group, suggestive of less intestinal permeability and subsequently lower MLN lymphocyte activation with supplementation (Table 1).
In addition to healthy weaning animals, there is support for a protective effect of glutamine in models of sepsis suggesting a therapeutic role for this amino acid in the infected animal (Table 1). Oral glutamine supplementation (1.1-2% w/v) prior to the induction of sepsis or endotoxemia increased the number of lymphocytes in PPs and lamina propria and normalized intestinal IgA levels of control animals[44–46]. Interestingly, even a single IV bolus of glutamine given immediately following the induction of sepsis appears to be protective. Previous studies have demonstrated that a 0.75 g/kg bolus of glutamine normalized systemic and intestinal inflammatory cytokine levels, increased the number of CD8αα + TCRαβ + and TCRγδ+/CD8αα + IELs , lowered the expression of inflammatory mediators in IELs and reduced IEL apoptosis[47, 48]. Glutamine supplementation (4% w/w) also increased the proportion of IgA + cells in the lamina propria in rat models of short bowel syndrome.
The importance of glutamine to the intestine is also evident when provided systemically. In healthy mice, a TPN solution containing 2% w/v glutamine was reported to restore intestinal IgA levels, the total number of lymphocytes in PPs, IEL and lamina propria, and improved intestinal levels of regulatory cytokines, IL-10 and IL-4[37, 50, 51].
Overall, animal studies have demonstrated that dietary supplementation with glutamine (0.5%–5% w/w) is required to maintain a healthy intestinal mucosa and support several GALT functions during weaning (lymphocyte counts and proliferative responses, decreased inflammatory cytokine production and increased immunoregulatory cytokines), infection (increased lymphocytes and sIgA levels, decreased inflammatory cytokine levels and IEL apoptosis, intestinal barrier function and structure and IEL proliferation and decreased oxidative stress) and other intestinal inflammatory states (increased sIgA levels). Providing glutamine systemically (TPN studies) have established the importance of glutamine to the health of the intestinal barrier (maintained intestinal structure and function) and for some GALT and other mucosal immune responses (maintained sIgA, lymphocyte and regulatory cytokine levels).
Glutamate is one of the most abundant dietary amino acids, but is found in very low concentrations in plasma[6, 52]. This is likely the result of glutamate being a major energy substrate for intestinal epithelial cells. It also serves as a precursor for other amino acids (L-alanine, L-aspartate, L-ornithine and L-proline) and for GSH in the intestine. GSH is essential to maintaining the thiol redox state, which is vital to adequate functioning of enterocytes and immune cells (Table 1).
Effects on intestinal function
Glutamate has a very low capacity to cross biological membranes, and enterocytes contain glutamate transporters in the plasma membrane making them one of the few cells that can rapidly transport and metabolize exogenous glutamate. This contributes to glutamate’s recognition as the single most important oxidative substrate for IECs. Dietary glutamate, as both a carbon and nitrogen donor, is the precursor of the conditionally essential amino acid, arginine. Maintaining endogenous arginine synthesis in piglet enterocytes has been demonstrated to be essential for optimal growth.
In vitro and in vivo studies have reported that providing glutamate can modulate the intestinal epithelium (Table 1). In an in vitro model of intestinal hyperpermeability (Caco2 cells), glutamate treatment reduced hyperpermeabilty up to 30%. Wu et al. reported that weanling piglets fed 1% w/w dietary glutamate for 20 days had increased jejunal villus height, mucosal thickness and intestinal epithelial cell proliferation. Although the immune functions of the intestine were not specifically measured in these studies, these changes would be consistent with improved intestinal immune function. However, Tsuchioka et al. reported that rats given TPN supplemented with glutamate (6.3% w/v) for 5 days had lower mucosal thickness and villous height in the small intestine relative to control TPN, suggesting a negative effect on the intestinal epithelium when glutamate is provided systemically.
Effects on immune function and GALT
Although immune cells produce considerable amounts of glutamate when provided glutamine, investigations into the effects of glutamate on immune cells are limited. It has been recently reported that T-cells, B-cells, dendritic cells and macrophages express glutamate receptors[59, 60], suggesting that glutamate likely has an important role in immune cell function. In support, Sturgill et al. reported that purified B-cells and peripheral mononuclear cells produced more IgG and IgE when cultured with glutamate in vitro. In T-cells, glutamate may function as an immunotransmitter, akin to its role as a neurotransmitter, as extracellular concentrations of glutamate have been shown to regulate T-cell responses (Table 1). Pacheco et al. demonstrated that dendritic cells release glutamate during antigen presentation to T-cells and this released glutamate influences T-cell proliferation and cytokine production. During the early stages of dendritic cell-T-cell interaction, glutamate binds to the constitutively expressed mGlu5R on T-cells to inhibit proliferation and cytokine production; however, later in the interaction glutamate binds to mGlu1R to induce T-cell proliferation and Th1 and proinflammatory cytokine production. This study demonstrates that glutamate plays an essential role in regulating antigen-specific T-cell activation and suggests that the high concentrations of glutamate in the intestine may play an important role in T-cell regulation in the gut.
Despite glutamate being present in high concentrations in the intestinal lumen and immune cells having unique glutamate receptors, there have not been dietary studies that have directly assessed the effect on GALT. Due to the high oxidation rate of glutamate by enterocytes and immune cells, and its role as a precursor for GSH and other amino acids it is reasonable to postulate that changes in the availability of glutamate modulates aspects of GALT (Table 1). We recently reviewed the evidence and presented a hypothesis for a novel role of glutamate receptors on immune cells as the means by which changes in glutamate availability modulates specific immune functions. In that review, we proposed that due to its immunosuppressive effects at concentrations above plasma levels, glutamate may have a key role in the development and maintenance of oral tolerance, a unique aspect of immunity in the intestine.
Despite the lack of investigation into the immune modulating properties of glutamate on GALT, it is likely that it has an essential role. To date, the effects of glutamate on GALT have not been examined in vivo. However, it is likely that glutamate has an essential role as an oxidative substrate to both enterocytes and immune cells. It is also a precursor for the synthesis of GSH, which is required to protect the intestinal mucosa and optimize immune cell function. And, finally, glutamate is a precursor for arginine, the substrate for the synthesis of NO. A high rate of NO synthesis by neutrophils is required during the innate immune response to infection. This is an important role of the immune system in the intestine.
Dietary glutamate appears essential for intestinal barrier function and likely other immune functions of the IEC, primarily as a precursor for GSH and as an oxidative substrate for enterocytes. Based on the available data, we can only hypothesize that the availability of glutamate to the cells in GALT has an immunoregulatory role. Studies conducted in systemic immune cells suggest that glutamate is essential for T-cell activation and B-cell immunoglobulin production and we postulate from indirect evidence that glutamate has a role in the induction of oral tolerance (that originates in GALT) and protection from enteric infections.
In most adult mammals, arginine is considered a dietary non-essential amino acid as it can be synthesized from glutamine, glutamate and proline, but becomes conditionally essential during periods of stress[63, 64]. Moreover, the absence of arginine in the diet has been shown to have adverse effects in adults, including reproductive, metabolic and neurological derangements. Arginine is classified as an essential amino acid in young mammals as endogenous synthesis cannot meet demands. Several studies have demonstrated that arginine supplementation, either to the piglet’s diet or to the lactating sow, improves growth performance in piglets[65–68]. The immune system is particularly sensitive to changes in arginine availability during early development and various disease states.
Arginine is the most plentiful nitrogen carrier in animals and is a precursor for urea, polyamines, proline, creatinine, agmatine, glutamate and protein. Perhaps most importantly, for the immune system, arginine is the only precursor for nitric oxide synthase (all isoforms) for the synthesis of nitric oxide (NO). In both the intestine and immune system, NO is essential for optimal functioning, including regulating the inflammatory response, facilitating killing of microbes by neutrophils and macrophages, and facilitating lymphocyte functions.
Effects on intestinal function
The structure and function of the intestine is sensitive to the amount of arginine in the diet during critical periods of development and disease states (Table 1). Studies have shown that arginine supplementation supports the growth and the development of the intestine and mucosal barrier in weanling piglets[65, 69, 70]. Dietary L-arginine supplementation ranging from 0.6% to 1.0% w/w increased intestinal growth, mucosa microvasculature (0.7% but not 1.2% w/w), villus height, crypt depth, and goblet cell counts in the piglets[65, 69, 70]. A proposed mechanism is that feeding arginine (0.6% w/w) increases expression of heat shock protein 70 (HSP70) which prevents protein denaturation and associated cellular stress.
In addition to supporting normal growth and development, supplementation with arginine has also been reported to reduce intestinal damage induced by E. coli derived LPS (Table 1). Sukhotnik et al. demonstrated that arginine (2% w/v in drinking water) ameliorated the adverse effects of LPS on the rat intestine, including improving intestinal weight, villous height, epithelial cell proliferation and mucosal DNA and protein. In addition, arginine (0.5 or 1.0% w/w) supplemented to weaned piglets abolished the villous atrophy and morphological changes induced by LPS infection. Arginine supplementation (1% v/v in water) lowered serum concentrations of endotoxin suggestive of improved gut permeability in a rat model of acute pancreatitis. In support of this finding, other researchers have reported that arginine supplementation reduces bacterial counts in mesenteric lymph nodes (4% w/w arginine) and improves gut barrier function (0.33 g/d arginine).
Effects on GALT
The immunomodulatory properties of L-arginine are well established and have been reviewed elsewhere[63, 76, 77]. Arginine has a fundamental role in both the innate and adaptive immune responses. One of the primary functions of arginine in leukocytes is as a substrate for inducible nitric oxide synthase (iNOS) to produce NO. Macrophages and neutrophils utilize NO to kill a variety of pathogens and malignant cells[63, 76]. NO also appears to be important for B-cell development and T-cell receptor function. The effects of arginine on GALT have been studied in both healthy and disease states and the available evidence suggest a beneficial effect on immune function.
Feeding arginine has been shown to be beneficial to GALT in inflammatory and trauma animal models, as well as healthy animals (Table 1). Rats fed diets containing 1% w/w arginine orally prior to the induction of acute pancreatitis had a higher proportion of T-helper cells and an increased ratio of CD4+:CD8+ cells in the intestinal lamina propria, as well as a greater concentration of fecal sIgA. Similarly, Fan et al. reported that supplementing arginine (1 g/kg) to severely burned mice for 7 days increased the number of lymphocytes isolated from PPs and intestinal IgA concentrations. Arginine supplemented mice (1 g/kg) also had intestinal cytokine profiles favouring a less inflammatory state (increased IL-4 and IL-10 and lower IFN-γ and IL-2). In chickens, feeding diets containing 2% w/w arginine improved intraepithelial cytotoxicity to viral infection and improved the antibody response to vaccine, suggesting effects on both cell types of the acquired immune system.
Animal models of TPN in both health and disease states have demonstrated that arginine supplementation can reverse the negative effects that TPN (not providing nutrients to the intestine) has on GALT. Mice supplemented with arginine (2 g/kg), prior to (oral diet) and following (TPN), had greater numbers of PPs and lymphocytes isolated from PPs, higher intestinal IgA levels and greater PHA-stimulated IL-10 production (splenocytes) relative to mice given no arginine prior to induction of sepsis. This study suggests that dietary arginine may be essential to maintaining the intestinal immune system during acute infection. Despite these improvements in immune parameters, arginine supplementation in this model of sepsis did not significantly improve survival. However, arginine supplementation to healthy animals fed by TPN also seems to have a similar beneficial effect on GALT. TPN supplemented with 1% w/v arginine given to healthy mice increased the proportion of αβTCR + T-cells and CD4+ T-cells in PPs and intraepithelial spaces compared to mice supplemented with 0.3% w/v arginine. These studies strongly support an essential role for a systemic supply of arginine to maintaining GALT, particularly when the intestine is not receiving nutrients directly from the diet.
There is considerable support that in health and stressed conditions oral ingestion of arginine (0.6% to 2% w/w) has a beneficial effect on GALT, with particular improvements in aspects of the acquired immune response. Arginine also supports the growth, development and maintenance of a healthy intestinal mucosa during critical periods of development (weaning) and under certain health conditions. These effects on the intestinal mucosa and GALT may be partly explained by arginine’s role as an essential precursor for NO.
Other amino acids
Methionine and cysteine–sulfur containing amino acids
The dietary essentiality of methionine and conditional essentiality of cysteine to humans and animals has been well established[82, 83]. Currently, there is little direct evidence demonstrating that these sulfur-containing amino acids alter immune function. However, indirectly their efficacy is supported by evidence that their metabolites (taurine, GSH and homocysteine) have immunomodulatory properties in vitro. GSH (also see glutamate section) functions as a free radical scavenger and may support proper immune cell function through a role in T-cell proliferation, and inflammatory cytokine regulation[6, 82, 83]. GSH also has a crucial role in protecting the intestinal epithelium from electrophile and fatty acid hydroperoxide damage. There is evidence that taurine and homocysteine have immunodulatory properties. Taurine is an end product of cysteine metabolism and diets devoid of taurine in cats resulted in reduced lymphocyte numbers, and mononuclear cells with impaired respiratory burst capacity. In vitro evidence suggests that taurine chloramine can suppress NF-kappaB activation and pro-inflammatory cytokine (IL-6 and TNF-α) production and in stimulated macrophages. In an in vitro model, homocysteine promoted monocyte activation and increased their adhesion to endothelial cells. At present there are no feeding studies to provide direct support for the effect of homocysteine or taurine on immune function in GALT.
There is some evidence that dietary methionine and cysteine are important to ensure the health of the intestine and immune function during development and in inflammatory states (Table 1). For example, Bauchart-Thevret et al. demonstrated that relative to healthy neonatal piglets fed a deficient diet, piglets supplemented with cysteine (0.25 g/kg) and methionine (25 g/kg) had less intestinal oxidative stress, improved villus height and area and crypt depth, higher number of goblet cells and Ki-67+ proliferative crypt cells. Cysteine also appears to be therapeutic in stressed inflammatory states, through improving intestinal inflammation and permeability. An infusion of L-cysteine (0.144 g/kg) given to pigs after DSS-induced colitis lowered mRNA expression of IL-8, MCP-1, MIP-1α, and MIP-2, and normalized IL-6, TNF- α, IFN-γ, IL-12, IL-1β and IL-10 in colon tissue. In addition, less inflammatory cell infiltration, crypt damage and lower intestinal permeability were observed in the pigs supplemented with L-cysteine (Table 1). While these studies demonstrate the importance of sulfur containing amino acids to gut health in healthy and stressed animals, there is no direct evidence of the effects on lymphocyte or macrophage cell function in GALT.
Threonine is a dietary essential amino acid that has been shown to have a particularly high retention rate in the intestine, which suggests an important function in the gut[55, 87]. Threonine has a major role in mucin synthesis, a glycoprotein that is required to protect the intestinal epithelium (Table 1). Mucin production is reduced in diets low or deficient in threonine in healthy rats and piglets[88–91]. Feeding a diet low in threonine (0.37% w/w) was found to adversely affect tight junction ultrastructure in the intestinal epithelium and induce villus atrophy in pigs[91, 92], supporting the importance of a dietary supply of threonine in maintaining gut barrier function. Consistent with this, threonine-deficient piglets were found to have higher paracellular permeability which would increase the risk of infectious organisms or their products coming in contact with the body. To date, there are no studies examining the effect of feeding threonine on the function of immune cells in GALT. However, Hamard et al. reported that pigs fed a 30%-reduced threonine diet for two weeks had increased expression of genes involved in inflammation and immunity in the ileum, including MHC Class I antigen (HLA-B), T-cell differentiation antigen CD6, and chemokine receptors. Chickens fed 0.4% w/w threonine in the diet for 8 weeks had higher IgA concentrations in the ileum than chickens fed 0%, 0.1% or 0.2% threonine, suggesting an effect on B cell function in the lamina propria (Table 1).
The intestine and the GALT are essential components of immune defense, protecting the animal/human from foreign antigens and pathogens, while allowing the absorption and tolerance of dietary nutrients. Feeding trials, primarily conducted in pigs and rodents, have established convincing evidence that not only the total protein intake but the availability of specific dietary amino acids, in particular glutamine, glutamate, and arginine, and perhaps methionine, cysteine and threonine, are essential to optimizing the immune functions of the intestine and specific immune cells located in GALT. These amino acids modulate their effects by maintaining the integrity, growth and immune functions of the epithelial cells in the intestine, as well as improve T-cell numbers and function, the secretion of IgA, and regulate inflammatory cytokine secretion. The studies conducted using feeding regimes (TPN) that bypass the oral route suggest that amino acids delivered in the blood from other parts of the body are important for maintaining GALT.
To date the majority of the studies have focussed on modulating single amino acids in a diet that contains many different proteins (combinations of amino acids) and determined function by measuring selective (often single parameters) functions. Evidence for some of these immunoactive amino acids comes primarily from in vitro studies or cells isolated from the systemic immune system (blood). Future studies should be designed using amino acid mixtures based on the existing knowledge to optimize immune function and growth in domestic animals and humans during critical periods of intestinal and GALT development in order to optimize health.
Follicle associated epithelium
Heat shock protein 70
Intestinal epithelial cell
Inducible nitric oxide
Gut-associated lymphoid tissue
Mesenteric lymph node
Tumour necrosis factor-alpha
Total parenteral nutrition.
Field CJ, Johnson IR, Schley PD: Nutrients and their role in host resistance to infection. J Leukoc Biol. 2002, 71: 16-32.
Wu GY, Field CJ, Marliss EB: Glutamine and glucose metabolism in thymocytes from normal and spontaneously diabetic BB rats. Biochem Cell Biol. 1991, 69: 801-808. 10.1139/o91-120.
Wu GY, Field CJ, Marliss EB: Elevated glutamine metabolism in splenocytes from spontaneously diabetic BB rats. Biochem J. 1991, 274 (Pt 1): 49-54.
Wu GY, Field CJ, Marliss EB: Glutamine and glucose metabolism in rat splenocytes and mesenteric lymph node lymphocytes. Am J Physiol. 1991, 260: E141-E147.
Field CJ, Wu G, Marliss EB: Enhanced metabolism of glucose and glutamine in mesenteric lymph node lymphocytes from spontaneously diabetic BB rats. Can J Physiol Pharmacol. 1994, 72: 827-832. 10.1139/y94-117.
Xue H, Field CJ: New role of glutamate as an immunoregulator via glutamate receptors and transporters. Front Biosci (Schol Ed). 2011, 3: 1007-1020.
Wu G: Functional amino acids in nutrition and health. Amino Acids. 2013, [Epub ahead of print]
Ziegler TR, Evans ME, Fernandez-Estivariz C, Jones DP: Trophic and cytoprotective nutrition for intestinal adaptation, mucosal repair, and barrier function. Annu Rev Nutr. 2003, 23: 229-261. 10.1146/annurev.nutr.23.011702.073036.
Wershil BK, Furuta GT: 4. Gastrointestinal mucosal immunity. J Allergy Clin Immunol. 2008, 121: S380-S383. 10.1016/j.jaci.2007.10.023.
Turner JR: Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 2009, 9: 799-809. 10.1038/nri2653.
Artis D: Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. Nat Rev Immunol. 2008, 8: 411-420. 10.1038/nri2316.
Kunisawa J, Takahashi I, Kiyono H: Intraepithelial lymphocytes: their shared and divergent immunological behaviors in the small and large intestine. Immunol Rev. 2007, 215: 136-153. 10.1111/j.1600-065X.2006.00475.x.
McGhee J: Mucosa-Associated Lymphoid Tissue (MALT). Encyclopedia of Immunology. Edited by: Roitt I, Delves P. 1998, United Kingdom: Elsevier Ltd, Academic Press Inc., 1774-1780. 2
Wyatt CR, Brackett EJ, Perryman LE, Davis WC: Identification of gamma delta T lymphocyte subsets that populate calf ileal mucosa after birth. Vet Immunol Immunopathol. 1996, 52: 91-103. 10.1016/0165-2427(95)05535-5.
Asai K, Komine Y, Kozutsumi T, Yamaguchi T, Komine K, Kumagai K: Predominant subpopulations of T lymphocytes in the mammary gland secretions during lactation and intraepithelial T lymphocytes in the intestine of dairy cows. Vet Immunol Immunopathol. 2000, 73: 233-240. 10.1016/S0165-2427(00)00158-6.
Bilsborough J, Viney JL: Getting to the guts of immune regulation. Immunology. 2002, 106: 139-143. 10.1046/j.1365-2567.2002.01445.x.
Newberry RD, Lorenz RG: Organizing a mucosal defense. Immunol Rev. 2005, 206: 6-21. 10.1111/j.0105-2896.2005.00282.x.
Rescigno M, Rotta G, Valzasina B, Ricciardi-Castagnoli P: Dendritic cells shuttle microbes across gut epithelial monolayers. Immunobiology. 2001, 204: 572-581. 10.1078/0171-2985-00094.
Brandtzaeg P: The gut as communicator between environment and host: immunological consequences. Eur J Pharmacol. 2011, 668 (Suppl 1): S16-S32.
Ruth MR, Proctor SD, Field CJ: Effects of feeding fish oil on mesenteric lymph node cytokine responses in obese leptin receptor-deficient JCR:LA-cp rats. Int J Obes (Lond). 2009, 33: 96-103. 10.1038/ijo.2008.227.
Zuckermann FA, Gaskins HR: Distribution of porcine CD4/CD8 double-positive T lymphocytes in mucosa-associated lymphoid tissues. Immunology. 1996, 87: 493-499. 10.1046/j.1365-2567.1996.494570.x.
Johnson IR, Ball RO, Baracos VE, Field CJ: Glutamine supplementation influences immune development in the newly weaned piglet. Dev Comp Immunol. 2006, 30: 1191-1202. 10.1016/j.dci.2006.03.003.
Brandtzaeg P: Mucosal immunity: induction, dissemination, and effector functions. Scand J Immunol. 2009, 70: 505-515. 10.1111/j.1365-3083.2009.02319.x.
McGhee JR, Mestecky J, Dertzbaugh MT, Eldridge JH, Hirasawa M, Kiyono H: The mucosal immune system: from fundamental concepts to vaccine development. Vaccine. 1992, 10: 75-88. 10.1016/0264-410X(92)90021-B.
Mantis NJ, Forbes SJ: Secretory IgA: arresting microbial pathogens at epithelial borders. Immunol Invest. 2010, 39: 383-406. 10.3109/08820131003622635.
Agarwal S, Mayer L: Pathogenesis and treatment of gastrointestinal disease in antibody deficiency syndromes. J Allergy Clin Immunol. 2009, 124: 658-664. 10.1016/j.jaci.2009.06.018.
Wu QY, Li F, Wang XY: Evidence that amino-acid residues are responsible for substrate synergism of locust arginine kinase. Insect Biochem Mol Biol. 2008, 38: 59-65. 10.1016/j.ibmb.2007.09.004.
Wu G, Meier SA, Knabe DA: Dietary glutamine supplementation prevents jejunal atrophy in weaned pigs. J Nutr. 1996, 126: 2578-2584.
Wu G: Amino acids: metabolism, functions, and nutrition. Amino Acids. 2009, 37: 1-17.
Wu G, Knabe DA, Yan W, Flynn NE: Glutamine and glucose metabolism in enterocytes of the neonatal pig. Am J Physiol. 1995, 268: R334-R342.
Wu G, Fang YZ, Yang S, Lupton JR, Turner ND: Glutathione metabolism and its implications for health. J Nutr. 2004, 134: 489-492.
Calder PC, Yaqoob P: Glutamine and the immune system. Amino Acids. 1999, 17: 227-241. 10.1007/BF01366922.
Domeneghini C, Di GA, Bosi G, Arrighi S: Can nutraceuticals affect the structure of intestinal mucosa? Qualitative and quantitative microanatomy in L-glutamine diet-supplemented weaning piglets. Vet Res Commun. 2006, 30: 331-342. 10.1007/s11259-006-3236-1.
Wang J, Chen L, Li P, Li X, Zhou H, Wang F, et al: Gene expression is altered in piglet small intestine by weaning and dietary glutamine supplementation. J Nutr. 2008, 138: 1025-1032.
O’Dwyer ST, Smith RJ, Hwang TL, Wilmore DW, et al : Maintenance of small bowel mucosa with glutamine-enriched parenteral nutrition. JPEN J Parenter Enteral Nutr. 1989, 13: 579-585. 10.1177/0148607189013006579.
Li J, Langkamp-Henken B, Suzuki K, Stahlgren LH, et al : Glutamine prevents parenteral nutrition-induced increases in intestinal permeability. JPEN J Parenter Enteral Nutr. 1994, 18: 303-307. 10.1177/0148607194018004303.
Nose K, Yang H, Sun X, Nose S, Koga H, Feng Y, et al: Glutamine prevents total parenteral nutrition-associated changes to intraepithelial lymphocyte phenotype and function: a potential mechanism for the preservation of epithelial barrier function. J Interferon Cytokine Res. 2010, 30: 67-80. 10.1089/jir.2009.0046.
Ewaschuk JB, Murdoch GK, Johnson IR, Madsen KL, Field CJ: Glutamine supplementation improves intestinal barrier function in a weaned piglet model of Escherichia coli infection. Br J Nutr. 2011, 106: 870-877. 10.1017/S0007114511001152.
Yi GF, Carroll JA, Allee GL, Gaines AM, Kendall DC, Usry JL, et al: Effect of glutamine and spray-dried plasma on growth performance, small intestinal morphology, and immune responses of Escherichia coli K88 + −challenged weaned pigs. J Anim Sci. 2005, 83: 634-643.
Haynes TE, Li P, Li X, Shimotori K, Sato H, Flynn NE, et al: L-Glutamine or L-alanyl-L-glutamine prevents oxidant- or endotoxin-induced death of neonatal enterocytes. Amino Acids. 2009, 37: 131-142. 10.1007/s00726-009-0243-x.
Vicario M, Amat C, Rivero M, Moreto M, Pelegri C: Dietary glutamine affects mucosal functions in rats with mild DSS-induced colitis. J Nutr. 2007, 137: 1931-1937.
Newsholme P: Why is L-glutamine metabolism important to cells of the immune system in health, postinjury, surgery or infection?. J Nutr. 2001, 131: 2515S-2522S.
Zhong X, Li W, Huang X, Wang Y, Zhang L, Zhou Y, et al: Effects of glutamine supplementation on the immune status in weaning piglets with intrauterine growth retardation. Arch Anim Nutr. 2012, 66: 347-356. 10.1080/1745039X.2012.683325.
Alverdy JA, Aoys E, Weiss-Carrington P, Burke DA: The effect of glutamine-enriched TPN on gut immune cellularity. J Surg Res. 1992, 52: 34-38. 10.1016/0022-4804(92)90275-5.
Lai YN, Yeh SL, Lin MT, Shang HF, Yeh CL, Chen WJ: Glutamine supplementation enhances mucosal immunity in rats with Gut-Derived sepsis. Nutrition. 2004, 20: 286-291. 10.1016/j.nut.2003.11.015.
Manhart N, Vierlinger K, Spittler A, Bergmeister H, Sautner T, Roth E: Oral feeding with glutamine prevents lymphocyte and glutathione depletion of Peyer’s patches in endotoxemic mice. Ann Surg. 2001, 234: 92-97. 10.1097/00000658-200107000-00014.
Lee WY, Hu YM, Ko TL, Yeh SL, Yeh CL: Glutamine modulates sepsis-induced changes to intestinal intraepithelial gammadeltaT lymphocyte expression in mice. Shock. 2012, 38: 288-293. 10.1097/SHK.0b013e3182655932.
Tung JN, Lee WY, Pai MH, Chen WJ, Yeh CL, Yeh SL: Glutamine modulates CD8alphaalpha TCRalphabeta intestinal intraepithelial lymphocyte expression in mice with polymicrobial sepsis. Nutrition. 2013, 29: 911-917. 10.1016/j.nut.2013.01.001.
Tian J, Hao L, Chandra P, Jones DP, Willams IR, Gewirtz AT, et al: Dietary glutamine and oral antibiotics each improve indexes of gut barrier function in rat short bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2009, 296: G348-G355.
Li J, Kudsk KA, Janu P, Renegar KB: Effect of glutamine-enriched total parenteral nutrition on small intestinal gut-associated lymphoid tissue and upper respiratory tract immunity. Surgery. 1997, 121: 542-549. 10.1016/S0039-6060(97)90109-4.
Kudsk KA, Wu Y, Fukatsu K, Zarzaur BL, Johnson CD, Wang R, et al: Glutamine-enriched total parenteral nutrition maintains intestinal interleukin-4 and mucosal immunoglobulin A levels. JPEN J Parenter Enteral Nutr. 2000, 24: 270-274. 10.1177/0148607100024005270.
Blachier F, Boutry C, Bos C, Tome D: Metabolism and functions of L-glutamate in the epithelial cells of the small and large intestines. Am J Clin Nutr. 2009, 90: 814S-821S. 10.3945/ajcn.2009.27462S.
Reeds PJ, Burrin DG, Stoll B, Jahoor F, Wykes L, Henry J, et al: Enteral glutamate is the preferential source for mucosal glutathione synthesis in fed piglets. Am J Physiol. 1997, 273: E408-E415.
Berger UV, Hediger MA: Distribution of the glutamate transporters GLT-1 (SLC1A2) and GLAST (SLC1A3) in peripheral organs. Anat Embryol (Berl). 2006, 211: 595-606. 10.1007/s00429-006-0109-x.
Reeds PJ: Dispensable and indispensable amino acids for humans. J Nutr. 2000, 130: 1835S-1840S.
Vermeulen MA, De Jong J, Vaessen MJ, van Leeuwen PA, Houdijk AP: Glutamate reduces experimental intestinal hyperpermeability and facilitates glutamine support of gut integrity. World J Gastroenterol. 2011, 17: 1569-1573. 10.3748/wjg.v17.i12.1569.
Wu X, Zhang Y, Liu Z, Li TJ, Yin YL: Effects of oral supplementation with glutamate or combination of glutamate and N-carbamylglutamate on intestinal mucosa morphology and epithelium cell proliferation in weanling piglets. J Anim Sci. 2012, 90 (Suppl 4): 337-339.
Tsuchioka T, Fujiwara T, Sunagawa M: Effects of glutamic acid and taurine on total parenteral nutrition. J Pediatr Surg. 2006, 41: 1566-1572. 10.1016/j.jpedsurg.2006.05.021.
Rezzani R, Corsetti G, Rodella L, Angoscini P, Lonati C, Bianchi R: Cyclosporine-A treatment inhibits the expression of metabotropic glutamate receptors in rat thymus. Acta Histochem. 2003, 105: 81-87. 10.1078/0065-1281-00688.
Sturgill JL, Mathews J, Scherle P, Conrad DH: Glutamate signaling through the kainate receptor enhances human immunoglobulin production. J Neuroimmunol. 2011, 233: 80-89. 10.1016/j.jneuroim.2010.11.014.
Pacheco R, Oliva H, Martinez-Navio JM, Climent N, Ciruela F, Gatell JM, et al: Glutamate released by dendritic cells as a novel modulator of T cell activation. J Immunol. 2006, 177: 6695-6704.
Nakamura H, Kawamata Y, Kuwahara T, Torii K, Sakai R: Nitrogen in dietary glutamate is utilized exclusively for the synthesis of amino acids in the rat intestine. Am J Physiol Endocrinol Metab. 2013, 304: E100-E108. 10.1152/ajpendo.00331.2012.
Li P, Yin YL, Li D, Kim SW, Wu G: Amino acids and immune function. Br J Nutr. 2007, 98: 237-252. 10.1017/S000711450769936X.
Wu G, Meininger CJ, Knabe DA, Bazer FW, Rhoads JM: Arginine nutrition in development, health and disease. Curr Opin Clin Nutr Metab Care. 2000, 3: 59-66. 10.1097/00075197-200001000-00010.
Wu X, Ruan Z, Gao Y, Yin Y, Zhou X, Wang L, et al: Dietary supplementation with L-arginine or N-carbamylglutamate enhances intestinal growth and heat shock protein-70 expression in weanling pigs fed a corn- and soybean meal-based diet. Amino Acids. 2010, 39: 831-839. 10.1007/s00726-010-0538-y.
Tan B, Li XG, Kong X, Huang R, Ruan Z, Yao K, et al: Dietary L-arginine supplementation enhances the immune status in early-weaned piglets. Amino Acids. 2009, 37: 323-331. 10.1007/s00726-008-0155-1.
Mateo RD, Wu G, Bazer FW, Park JC, Shinzato I, Kim SW: Dietary L-arginine supplementation enhances the reproductive performance of gilts. J Nutr. 2007, 137: 652-656.
Kim SW, Wu G: Dietary arginine supplementation enhances the growth of milk-fed young pigs. J Nutr. 2004, 134: 625-630.
Yao K, Guan S, Li T, Huang R, Wu G, Ruan Z, et al: Dietary L-arginine supplementation enhances intestinal development and expression of vascular endothelial growth factor in weanling piglets. Br J Nutr. 2011, 105: 703-709. 10.1017/S000711451000365X.
Zhan Z, Ou D, Piao X, Kim SW, Liu Y, Wang J: Dietary arginine supplementation affects microvascular development in the small intestine of early-weaned pigs. J Nutr. 2008, 138: 1304-1309.
Sukhotnik I, Mogilner J, Krausz MM, Lurie M, Hirsh M, Coran AG, et al: Oral arginine reduces gut mucosal injury caused by lipopolysaccharide endotoxemia in rat. J Surg Res. 2004, 122: 256-262. 10.1016/j.jss.2004.07.004.
Zhu H, Liu Y, Xie X, Huang J, Hou Y: Effect of L-arginine on intestinal mucosal immune barrier function in weaned pigs after Escherichia coli LPS challenge. Innate Immun. 2013, 19: 242-252. 10.1177/1753425912456223.
Qiao SF, Lu TJ, Sun JB, Li F: Alterations of intestinal immune function and regulatory effects of L-arginine in experimental severe acute pancreatitis rats. World J Gastroenterol. 2005, 11: 6216-6218.
Gurbuz AT, Kunzelman J, Ratzer EE: Supplemental dietary arginine accelerates intestinal mucosal regeneration and enhances bacterial clearance following radiation enteritis in rats. J Surg Res. 1998, 74: 149-154. 10.1006/jsre.1997.5231.
Ersin S, Tuncyurek P, Esassolak M, Alkanat M, Buke C, Yilmaz M, et al: The prophylactic and therapeutic effects of glutamine- and arginine-enriched diets on radiation-induced enteritis in rats. J Surg Res. 2000, 89: 121-125. 10.1006/jsre.1999.5808.
Field CJ, Johnson I, Pratt VC: Glutamine and arginine: immunonutrients for improved health. Med Sci Sports Exerc. 2000, 32: S377-S388. 10.1097/00005768-200007001-00002.
Popovic PJ, Zeh HJ, Ochoa JB: Arginine and immunity. J Nutr. 2007, 137: 1681S-1686S.
Fan J, Meng Q, Guo G, Xie Y, Li X, Xiu Y, et al: Effects of early enteral nutrition supplemented with arginine on intestinal mucosal immunity in severely burned mice. Clin Nutr. 2010, 29: 124-130. 10.1016/j.clnu.2009.07.005.
Tayade C, Koti M, Mishra SC: L-Arginine stimulates intestinal intraepithelial lymphocyte functions and immune response in chickens orally immunized with live intermediate plus strain of infectious bursal disease vaccine. Vaccine. 2006, 24: 5473-5480. 10.1016/j.vaccine.2006.03.086.
Shang HF, Wang YY, Lai YN, Chiu WC, Yeh SL: Effects of arginine supplementation on mucosal immunity in rats with septic peritonitis. Clin Nutr. 2004, 23: 561-569. 10.1016/j.clnu.2003.10.005.
Fukatsu K, Ueno C, Maeshima Y, Hara E, Nagayoshi H, Omata J, et al: L-arginine-enriched parenteral nutrition affects lymphocyte phenotypes of gut-associated lymphoid tissue. JPEN J Parenter Enteral Nutr. 2004, 28: 246-250. 10.1177/0148607104028004246.
Grimble RF: The effects of sulfur amino acid intake on immune function in humans. J Nutr. 2006, 136: 1660S-1665S.
Shoveller AK, Stoll B, Ball RO, Burrin DG: Nutritional and functional importance of intestinal sulfur amino acid metabolism. J Nutr. 2005, 135: 1609-1612.
Koga T, Claycombe K, Meydani M: Homocysteine increases monocyte and T-cell adhesion to human aortic endothelial cells. Atherosclerosis. 2002, 161: 365-374. 10.1016/S0021-9150(01)00670-0.
Bauchart-Thevret C, Stoll B, Chacko S, Burrin DG: Sulfur amino acid deficiency upregulates intestinal methionine cycle activity and suppresses epithelial growth in neonatal pigs. Am J Physiol Endocrinol Metab. 2009, 296: E1239-E1250. 10.1152/ajpendo.91021.2008.
Kim CJ, Kovacs-Nolan J, Yang C, Archbold T, Fan MZ, Mine Y: L-cysteine supplementation attenuates local inflammation and restores gut homeostasis in a porcine model of colitis. Biochim Biophys Acta. 2009, 1790: 1161-1169. 10.1016/j.bbagen.2009.05.018.
Stoll B, Henry J, Reeds PJ, Yu H, Jahoor F, Burrin DG: Catabolism dominates the first-pass intestinal metabolism of dietary essential amino acids in milk protein-fed piglets. J Nutr. 1998, 128: 606-614.
Law GK, Bertolo RF, Adjiri-Awere A, Pencharz PB, Ball RO: Adequate oral threonine is critical for mucin production and gut function in neonatal piglets. Am J Physiol Gastrointest Liver Physiol. 2007, 292: G1293-G1301.
Faure M, Moennoz D, Montigon F, Mettraux C, Breuille D, Ballevre O: Dietary threonine restriction specifically reduces intestinal mucin synthesis in rats. J Nutr. 2005, 135: 486-491.
Nichols NL, Bertolo RF: Luminal threonine concentration acutely affects intestinal mucosal protein and mucin synthesis in piglets. J Nutr. 2008, 138: 1298-1303.
Wang W, Zeng X, Mao X, Wu G, Qiao S: Optimal dietary true ileal digestible threonine for supporting the mucosal barrier in small intestine of weanling pigs. J Nutr. 2010, 140: 981-986. 10.3945/jn.109.118497.
Hamard A, Mazurais D, Boudry G, Le Huerou-Luron I, Seve B, Le FN: A moderate threonine deficiency affects gene expression profile, paracellular permeability and glucose absorption capacity in the ileum of piglets. J Nutr Biochem. 2010, 21: 914-921. 10.1016/j.jnutbio.2009.07.004.
Azzam MM, Zou XT, Dong XY, Xie P: Effect of supplemental L-threonine on mucin 2 gene expression and intestine mucosal immune and digestive enzymes activities of laying hens in environments with high temperature and humidity. Poult Sci. 2011, 90: 2251-2256. 10.3382/ps.2011-01574.
We thank Ms. Amanda Leong and Ms. Xiaoming Jia for their assistance in developing the figure for this manuscript. This work was supported by CJ Field’s funding from the Natural Sciences and Engineering Council of Canada (NSERC).
MRR and CJF do not have any competing interests to disclose.
CJF conceived of the manuscript’s purpose and design and critically revised the manuscript. MRR wrote and revised the manuscript according to CJF’s suggestions. Both authors read and approved the final manuscript submitted.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.